NCT01005628View on ClinicalTrials.gov

Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)

CompletedOBSERVATIONAL
Enrollment

1,121

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

Injection into a vein 1.3 mg/m2 twice a week for 21 days

Trial Locations (1)

Unknown

Seoul

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01005628 - Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) | Biotech Hunter | Biotech Hunter